Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2017
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Phentermine
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Jun 2017 Results (n=334) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Mar 2017 Results assessing effectiveness of Canagliflozin and Phentermine for weight management in overweight and obese individuals without diabetes published in the Diabetes Care.
- 16 Sep 2016 Results (n=334) assessing efficacy and safety, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.